Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods - McKinnon Direct Packaging & Fulfilment Pty Ltd, The Australian Red Cross Blood Service - an Operating Division of the Australian Red Cross Society

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth of Australia's Parliament, aims to regulate therapeutic goods to ensure their safety, quality, and efficacy. This Act provides a comprehensive framework for the control and oversight of therapeutic goods, including medicines, medical devices, and blood products. The Act was introduced to address the need for stringent regulation to protect public health by ensuring that only safe and effective therapeutic goods are available in the market. The Therapeutic Goods Administration, under the Department of Health, is the relevant body responsible for enforcing this legislation, with the aim of achieving high standards in the manufacture, supply, and advertising of therapeutic goods. On 12 August 2014, Dr. Harry Rothenfluh, as a delegate of the Secretary of the Department of Health for the Therapeutic Goods Administration, published details concerning the revocation of manufacturing licences for two entities. McKinnon Direct Packaging & Fulfilment Pty Ltd and The Australian Red Cross Blood Service, an operating division of The Australian Red Cross Society, had their licences revoked at the request of the manufacturers themselves, under Section 41(1)(d) of the Therapeutic Goods Act 1989. This action highlights the regulatory authority's commitment to maintaining high standards in the therapeutic goods industry, ensuring that any entity involved in the manufacture of these products adheres to stringent regulatory requirements.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) within the Department of Health, applies to any person or entity involved in the supply, import, export, or manufacture of therapeutic goods in Australia. This includes a wide range of products such as medicines, medical devices, blood, and tissues, and it covers all activities from research and development through to the retail sale. The Act's jurisdiction is nationwide, applying to all states and territories within the Commonwealth of Australia. Under the Act, certain exclusions apply, particularly to goods that fall under other legislative regimes such as food or cosmetics that may also have therapeutic claims. The application and enforcement of the Act can be extended or restricted through subordinate instruments, which allow the TGA to issue guidelines, codes, and standards that further clarify and implement the legislative requirements. These instruments aid in ensuring that therapeutic goods meet safety, quality, and efficacy standards before they enter the market.

Key Provisions

The Therapeutic Goods Act 1989, as amended, provides the legal framework governing the regulation of therapeutic goods in Australia. Section 41(1)(d) of the Act allows the Secretary to revoke a licence to manufacture therapeutic goods under specific circumstances. The recent Gazette publication by Dr. Harry Rothenfluh, the Delegate of the Secretary, pertains to the revocation of two manufacturing licences. Section 41(1)(d) empowers the Secretary to revoke a licence if the manufacturer requests it, and this applies to McKinnon Direct Packaging & Fulfilment Pty Ltd (Licence No. MI-22042005-LI-000518-1, Original Licence No. 123241) and The Australian Red Cross Blood Service (Licence No. MI-23082005-LI-000834-1, Original Licence No. 1442). The Act imposes specific obligations on manufacturers of therapeutic goods, including compliance with manufacturing standards, proper record-keeping, and adherence to guidelines for the production of safe and effective products. The revocation of a licence under Section 41(1)(d) occurs at the request of the manufacturer, which implies an agreement between the manufacturer and the Secretary regarding the cessation of manufacturing activities. Such a revocation ensures that only entities capable of meeting regulatory standards continue to operate within the therapeutic goods market. Breaches of the Therapeutic Goods Act 1989 can lead to both civil and criminal consequences. The Act does not specify particular offences directly linked to the revocation of a manufacturing licence but outlines severe penalties for violations concerning the manufacture, supply, and advertisement of therapeutic goods. Offences may include manufacturing goods that do not comply with standards, resulting in potential fines and imprisonment. For instance, under Section 34(1) of the Act, a person who contravenes a provision of the Act can be fined up to $222,200 for a corporation and $44,440 for an individual, in addition to or instead of imprisonment for up to five years. The severity of these penalties underscores the importance of compliance with the Act’s provisions.